TN2013000216A1 - Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine - Google Patents

Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine

Info

Publication number
TN2013000216A1
TN2013000216A1 TNP2013000216A TN2013000216A TN2013000216A1 TN 2013000216 A1 TN2013000216 A1 TN 2013000216A1 TN P2013000216 A TNP2013000216 A TN P2013000216A TN 2013000216 A TN2013000216 A TN 2013000216A TN 2013000216 A1 TN2013000216 A1 TN 2013000216A1
Authority
TN
Tunisia
Prior art keywords
phenyl
crystalline forms
piperidin
isopropoxy
diamine
Prior art date
Application number
TNP2013000216A
Other languages
English (en)
Inventor
Lili Feng
Baoqing Gong
Piotr H Karpinski
Liladhar Murlidhar Waykole
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45464892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000216(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2013000216A1 publication Critical patent/TN2013000216A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
TNP2013000216A 2010-12-17 2013-05-17 Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine TN2013000216A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061424194P 2010-12-17 2010-12-17
PCT/US2011/065030 WO2012082972A1 (fr) 2010-12-17 2011-12-15 Formes cristallines de la 5-chloro-n2-(2-isopropoxy-5-méthyl-4-pipéridin-4-yl-phényl)-n4[2-(propane-2-sulfonyl)-phényl]-pyrimidine-2,4-diamine

Publications (1)

Publication Number Publication Date
TN2013000216A1 true TN2013000216A1 (en) 2014-11-10

Family

ID=45464892

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000216A TN2013000216A1 (en) 2010-12-17 2013-05-17 Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine

Country Status (35)

Country Link
US (2) US9309229B2 (fr)
EP (3) EP2651918B1 (fr)
JP (1) JP5916752B2 (fr)
KR (4) KR20130130022A (fr)
CN (7) CN104262324A (fr)
AR (2) AR084309A1 (fr)
AU (1) AU2011343775B2 (fr)
BR (1) BR112013015000A2 (fr)
CA (1) CA2821102C (fr)
CL (1) CL2013001723A1 (fr)
CO (1) CO6801792A2 (fr)
CY (2) CY1119474T1 (fr)
DK (2) DK2651918T3 (fr)
EC (1) ECSP13012770A (fr)
ES (3) ES2643016T3 (fr)
GT (1) GT201300153A (fr)
HR (2) HRP20171477T1 (fr)
HU (1) HUE041845T2 (fr)
IL (1) IL226474A (fr)
LT (2) LT2651918T (fr)
MA (1) MA34771B1 (fr)
MX (1) MX338210B (fr)
MY (2) MY164810A (fr)
NZ (1) NZ610713A (fr)
PE (1) PE20140698A1 (fr)
PL (2) PL2651918T3 (fr)
PT (2) PT2651918T (fr)
RS (1) RS57771B1 (fr)
RU (2) RU2599785C3 (fr)
SG (2) SG10201510082XA (fr)
SI (2) SI3121171T1 (fr)
TN (1) TN2013000216A1 (fr)
TW (2) TWI576343B (fr)
WO (1) WO2012082972A1 (fr)
ZA (1) ZA201303599B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011343775B2 (en) 2010-12-17 2015-12-03 Novartis Ag Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl- 4-piperidin-4-yl-phenyl)-N4[2-(propane-2-sulfonyl)-phenyl] -pyrimidine-2,4-diamine
AU2013344049B2 (en) 2012-11-06 2017-12-21 Fochon Pharmaceuticals, Ltd. ALK kinase inhibitors
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
CN105272921A (zh) * 2014-06-09 2016-01-27 江苏奥赛康药业股份有限公司 一种制备Ceritinib的方法及其中间体化合物
CN105294649B (zh) * 2014-07-30 2019-05-14 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
CN105294650A (zh) * 2014-08-01 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
TN2017000157A1 (en) 2014-10-21 2018-10-19 Ariad Pharma Inc Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine
WO2016081538A1 (fr) 2014-11-18 2016-05-26 Teva Pharmaceuticals International Gmbh Formes solides de ceritinib et sels de ceux-ci
CN105601614A (zh) * 2014-11-21 2016-05-25 奥浦顿（上海）医药科技有限公司 一种色瑞替尼晶型及其制备方法
WO2016082795A1 (fr) * 2014-11-28 2016-06-02 苏州晶云药物科技有限公司 Forme cristalline i du ceritinib et son procédé de préparation
CN105622577A (zh) * 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
WO2016108123A2 (fr) * 2014-12-17 2016-07-07 Dr. Reddy’S Laboratories Limited Forme amorphe pure et dispersion solide amorphe de céritinib
WO2016098070A1 (fr) 2014-12-19 2016-06-23 Novartis Ag Forme cristalline de la 5-chloro-n2-(2-isopropoxy-5-méthyl-4-pipéridin-4-yl-phényl)-n4-[2-(propane-2-sulfonyl)-phényl]-pyrimidine-2,4-diamine
WO2016098042A1 (fr) * 2014-12-19 2016-06-23 Novartis Ag Utilisation du céritinib (ldk -378) dans le traitement de troubles médiés par fes ou fer, en particulier des troubles prolifératifs
EP3328848A1 (fr) 2015-07-28 2018-06-06 Zentiva, K.S. Formes solides de ceritinib base libre
CN105061397B (zh) * 2015-08-07 2018-01-02 武汉英普瑞医药科技有限公司 一种色瑞替尼的c型晶型及其制备方法与应用
CN106699743B (zh) 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
WO2017152858A1 (fr) * 2016-03-11 2017-09-14 苏州晶云药物科技有限公司 Forme cristalline de céritinib et procédé pour sa préparation
WO2017158619A1 (fr) 2016-03-15 2017-09-21 Natco Pharma Limited Procédé modifié pour la préparation de céritinib et de forme amorphe de céritinib
JP2019196359A (ja) * 2019-06-17 2019-11-14 ノバルティス アーゲー ピリミジン誘導体およびそれらの中間体を調製する化学的方法
GB201915618D0 (en) 2019-10-28 2019-12-11 Univ Oslo ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
US20230348443A1 (en) * 2020-01-17 2023-11-02 Shandong Xuanzhu Pharma Co., Ltd. Crystal form of polycyclic anaplastic lymphoma kinase inhibitor

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
MXPA06001759A (es) * 2003-08-15 2006-05-12 Novartis Ag 2,4-pirimidinadiaminas utiles en el tratamiento de enfermedades neoplasticas, desordenes del sistema inmune e inflamatorios.
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
CA2671744C (fr) * 2006-12-08 2012-08-28 Irm Llc Composes et compositions inhibant la proteine kinase
UA100846C2 (uk) 2006-12-08 2013-02-11 Айерем Елелсі Сполуки та композиція як інгібітори протеїнкінази
BRPI0815979A2 (pt) * 2007-08-28 2017-06-13 Irm Llc compostos e composições com inibidores de quinase, bem como uso dos mesmos
WO2009032694A1 (fr) * 2007-08-28 2009-03-12 Dana Farber Cancer Institute Pyrimidine substituée par amino, dérivés de pyrollopyridine et de pyrazolopyrimidine utilisés en tant qu'inhibiteurs de la kinase et dans le traitement de troubles prolifératifs et de maladies liées à l'angiogenèse
US8592432B2 (en) * 2008-04-07 2013-11-26 Bei Chen Compounds and compositions as protein kinase inhibitors
HUE035029T2 (en) * 2008-05-21 2018-03-28 Ariad Pharma Inc Kinase inhibitor phosphorus derivatives
EP2440534A2 (fr) * 2009-06-10 2012-04-18 Cellzome Limited Dérivés de pyrimidine en tant qu'inhibiteurs zap-70
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
JP2014501246A (ja) 2010-12-17 2014-01-20 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺菌・殺カビ性アゾ環式アミド
AU2011343775B2 (en) 2010-12-17 2015-12-03 Novartis Ag Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl- 4-piperidin-4-yl-phenyl)-N4[2-(propane-2-sulfonyl)-phenyl] -pyrimidine-2,4-diamine
WO2012083306A2 (fr) 2010-12-17 2012-06-21 Reata Pharmaceuticals, Inc. Pyrazolyl- et pyrimidinyl-énones tricycliques en tant que modulateurs d'inflammation antioxydants
CN105294650A (zh) 2014-08-01 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
WO2016081538A1 (fr) 2014-11-18 2016-05-26 Teva Pharmaceuticals International Gmbh Formes solides de ceritinib et sels de ceux-ci
CN107107792B (zh) 2014-11-21 2020-05-19 Tk控股公司 气囊模块
CN105622577A (zh) 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
JP2017537927A (ja) 2014-12-04 2017-12-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ がん（骨髄腫）を処置するための抗ｃｓ１および抗ｐｄ１抗体の併用
WO2016098070A1 (fr) 2014-12-19 2016-06-23 Novartis Ag Forme cristalline de la 5-chloro-n2-(2-isopropoxy-5-méthyl-4-pipéridin-4-yl-phényl)-n4-[2-(propane-2-sulfonyl)-phényl]-pyrimidine-2,4-diamine
EP3328848A1 (fr) 2015-07-28 2018-06-06 Zentiva, K.S. Formes solides de ceritinib base libre
CN105061397B (zh) 2015-08-07 2018-01-02 武汉英普瑞医药科技有限公司 一种色瑞替尼的c型晶型及其制备方法与应用

Also Published As

Publication number Publication date
SG10201510082XA (en) 2016-01-28
PE20140698A1 (es) 2014-06-11
SI2651918T1 (sl) 2017-10-30
BR112013015000A2 (pt) 2016-08-09
CL2013001723A1 (es) 2013-12-27
KR20190022903A (ko) 2019-03-06
RU2016136823A (ru) 2018-12-11
AR122395A2 (es) 2022-09-07
US9309229B2 (en) 2016-04-12
TWI576344B (zh) 2017-04-01
ECSP13012770A (es) 2013-10-31
TWI576343B (zh) 2017-04-01
MY177742A (en) 2020-09-23
MX338210B (es) 2016-04-07
AU2011343775A1 (en) 2013-07-18
MA34771B1 (fr) 2013-12-03
ZA201303599B (en) 2014-02-26
NZ610713A (en) 2014-10-31
KR20180032680A (ko) 2018-03-30
CO6801792A2 (es) 2013-11-29
TW201307299A (zh) 2013-02-16
US20130274279A1 (en) 2013-10-17
DK3121171T3 (en) 2018-12-10
KR20200039021A (ko) 2020-04-14
IL226474A (en) 2016-03-31
RU2599785C3 (ru) 2019-04-24
RU2599785C2 (ru) 2016-10-20
EP2651918A1 (fr) 2013-10-23
MY164810A (en) 2018-01-30
CN112125884A (zh) 2020-12-25
CY1121017T1 (el) 2019-12-11
US20160175305A1 (en) 2016-06-23
PT3121171T (pt) 2018-11-27
EP3453708A1 (fr) 2019-03-13
EP3453708B8 (fr) 2022-03-16
KR20130130022A (ko) 2013-11-29
RU2746159C2 (ru) 2021-04-08
SI3121171T1 (sl) 2018-11-30
JP5916752B2 (ja) 2016-05-11
EP2651918B1 (fr) 2017-07-12
CN114989139A (zh) 2022-09-02
RS57771B1 (sr) 2018-12-31
HRP20181737T1 (hr) 2018-12-28
CN106008462A (zh) 2016-10-12
EP3453708B1 (fr) 2021-10-27
KR102325775B1 (ko) 2021-11-12
PT2651918T (pt) 2017-10-17
TW201629021A (zh) 2016-08-16
SG190856A1 (en) 2013-07-31
ES2643016T3 (es) 2017-11-21
IL226474A0 (en) 2013-07-31
MX2013006952A (es) 2013-07-15
CN103282359A (zh) 2013-09-04
PL3121171T3 (pl) 2019-01-31
AU2011343775B2 (en) 2015-12-03
AR084309A1 (es) 2013-05-08
ES2905973T3 (es) 2022-04-12
CN106831716A (zh) 2017-06-13
ES2696526T3 (es) 2019-01-16
RU2016136823A3 (fr) 2020-02-06
CA2821102C (fr) 2019-06-11
HRP20171477T1 (hr) 2017-11-17
GT201300153A (es) 2014-06-09
CA2821102A1 (fr) 2012-06-21
WO2012082972A1 (fr) 2012-06-21
CN104262324A (zh) 2015-01-07
EP3121171B1 (fr) 2018-08-15
DK2651918T3 (en) 2017-10-23
HUE041845T2 (hu) 2019-05-28
CN107056751A (zh) 2017-08-18
CY1119474T1 (el) 2018-04-04
LT2651918T (lt) 2017-10-10
PL2651918T3 (pl) 2017-12-29
EP3121171A1 (fr) 2017-01-25
RU2013132947A (ru) 2015-01-27
JP2013545812A (ja) 2013-12-26
LT3121171T (lt) 2018-11-12

Similar Documents

Publication Publication Date Title
TN2013000216A1 (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
EA201590930A1 (ru) Лекарственные формы руксолитиниба с замедленным высвобождением
PL3290414T3 (pl) Sposób otrzymywania n-[5-(3,5-difluorobenzylo)-1h-indazol-3-ilo]-4-(4-metylopiperazyn-1-ylo)-2-(tetrahydropiran-4-yloamino)benzamidu
EA201290772A1 (ru) Новые формы ивабрадина гидрохлорида
EA201391318A1 (ru) Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2,6-диона и их фармацевтические композиции и применение
PH12015501955B1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
EA201101194A1 (ru) Применение розувастатин лактолов в качестве лекарственных препаратов
AR088936A1 (es) Formulaciones farmaceuticas
MY180581A (en) A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
EP3031465A4 (fr) Composition pharmaceutique pour favoriser la formation de tissu osseux, contenant un extrait de feuille de stauntonia hexaphylla comme principe actif
EA201001870A1 (ru) Новые кристаллические формы рабепразола натрия
EA200970816A1 (ru) Новая лекарственная форма
TN2016000207A1 (en) Pharmaceutical dosage forms.
EA201390768A1 (ru) Способ получения солей розувастатина
EA201400444A1 (ru) Производные 2-оксопиперидинила
AU2012312301A8 (en) Compounds useful as inhibitors of choline kinase
MX2012010491A (es) Compuestos arilvinilazacicloalcano para la constipacion.
MX351994B (es) Formas cristalinas de [(s)-1-carbamoil-2-(feniil-pirimidin-2-il-am ino)-etil]-amida del acido 2-(2-metilamino-pirimidin-4-il)-1h-indo l-5-carboxilico.
UA103544C2 (uk) Кристалічна форма і цинкової солі розувастатину
EA201390700A1 (ru) Кристаллические фармацевтически активные ингредиенты
TH145940A (th) รูปผลึกของ 5-คลอโร-n2-(2-ไอโซโพรพอกซี-5-เมธิล-4-ไพเพอริดิน-4-อิล-เฟนิล)-n4-[2-(โพรเพน-2-ซัลโฟนิล)-เฟนิล]-ไพริมิดีน-2,4-ไดเอมีน